GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Using nanotechnology to engineer sensors onto the surface of cells, researchers at Brigham and Women’s Hospital have developed a platform technology for monitoring single-cell interactions in real-time. The scientists believe that this innovation addresses needs in both science and medicine by providing the ability to further understand complex cell biology, track transplanted cells, and develop effective therapeutics.

During this week’s podcast Dr. Jeffrey Karp provides additional details on this novel system for monitoring cellular interactions. Dr. Karp, who was recognized by the Boston Business Journal as a Champion in Healthcare Innovation, also discusses how currently used cell-signaling sensors operate and describes the advantages of his team’s new approach.

Jeffrey M. Karp is an assistant professor at Harvard Medical School and is co-director of the Center for Regenerative Therapeutics at the Brigham and Women's Hospital. He also holds appointments at the Harvard Stem Cell Institute and MIT. He obtained his Ph.D. from the University of Toronto. His research currently spans stem cell engineering, biomaterials, and medical devices. Dr. Karp has published more than 50 peer-reviewed papers, 15 book chapters, 60 abstracts, and has 25 issued or pending patents. He currently serves as the biology and medicine section editor for Journal Nanotechnology.

Add a comment

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »